BJH - volume 15, issue 7, november 2024
S. Marchetta MD, C. Douin MD, T. Couvreur MD, J. Djekic MD, B. Bastens MD, G. Houbiers MD, B. Massart MD, R. Roufosse MD, L. Longrée , C. Focan MD, PhD
The authors report the case of a patient suffering from cardiac amyloidosis with hepatic involvement. A prolonged remission was obtained under chemoimmunotherapy with CyBorD association (cyclophosphamide, bortezomib, and dexamethasone) and daratumumab. A literature survey is performed and presented.
(BELG J HEMATOL 2024;15(7):281–5)
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.